<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MILLIPRED- prednisolone sodium phosphate solution </strong><br>Laser Pharmaceuticals, LLC<br></p></div>
<h1>Millipred™ <br>(Prednisolone Sodium Phosphate Oral Solution, <br>10 mg Prednisolone Base per 5 mL)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Millipred Oral Solution (10 mg Prednisolone per 5 mL) is a dye free, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> to light yellow solution. Each 5 mL (teaspoonful) of Millipred Oral Solution contains 13.4 mg prednisolone sodium phosphate (10 mg prednisolone base) in a palatable, aqueous vehicle.</p>
<p>Inactive Ingredients: Millipred Oral Solution (10 mg Prednisolone per 5 mL) contains the following inactive ingredients: anti-bitter mask, corn syrup, edetate disodium, glycerin, grape flavor, hydroxyethylcellulose, methylparaben, potassium phosphate dibasic, potassium phosphate monobasic, purified water, and sodium saccharin.</p>
<p>Prednisolone sodium phosphate occurs as white or slightly yellow, friable granules or powder. It is freely soluble in water; soluble in methanol; slightly soluble in alcohol and in chloroform; and very slightly soluble in acetone and in dioxane.The chemical name of prednisolone sodium phosphate is pregna-1,4-diene-3,20-dione,11,17-dihydroxy-21- (phosphonooxy)- disodium salt, (11β)-. The empirical formula is C<span class="Sub">21</span>H<span class="Sub">27</span>Na<span class="Sub">2</span>O<span class="Sub">8</span>P; the molecular weight is 484.39. Its chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89&amp;name=millipred-01.jpg"></div>
<p>Pharmacological Category: Glucocorticoid</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.</p>
<p>Prednisolone is a synthetic adrenocortical steroid drug with predominantly glucocorticoid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones' normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisolone which are due to its glucocorticoid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion.</p>
<p>Depressed production of eosinophils and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited.</p>
<p>Prednisolone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisolone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Prednisolone is rapidly and well absorbed from the gastrointestinal tract following oral administration. Millipred Oral Solution (10 mg Prednisolone per 5 mL) produces a 14% higher peak plasma level of prednisolone which occurs 20% faster than that seen with tablets. Prednisolone is 70-90% protein bound in the plasma, and it is eliminated from the plasma with a half-life of 2 to 4 hours. It is metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates.</p>
<p>The systemic availability, metabolism and elimination of prednisolone after administration of single weight-based doses (0.8 mg/kg) of intravenous (IV) prednisolone and oral prednisone were reported in a small study of 19 young (23 to 34 years) and 12 elderly (65 to 89 years) subjects. Results showed that the systemic availability of total and unbound prednisolone, as well as interconversion between prednisolone and prednisone were independent of age. The mean unbound fraction of prednisolone was higher, and steady-state volume of distribution (Vss) of unbound prednisolone was reduced in elderly patients. Plasma prednisolone concentrations were higher in elderly subjects, and the higher AUCs of total and unbound prednisolone were most likely reflective of an impaired metabolic clearance, evidenced by reduced fractional urinary clearance of 6β-hydroxyprednisolone. Despite these findings of higher total and unbound prednisolone concentrations, elderly subjects had higher AUCs of cortisol, suggesting that the elderly population is less sensitive to suppression of endogenous cortisol or their capacity for hepatic inactivation of cortisol is diminished.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Millipred Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>1. Allergic States</h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>; <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>; <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>; <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>2. Dermatologic Diseases</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span>; <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span> herpetiformis; severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>); exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>; <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>3. Edematous States</h2>
<p class="First">To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in adults with <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span> and in adults and pediatric populations, with idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></h2>
<p class="First">Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>; <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer; nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>5. Gastrointestinal Diseases</h2>
<p class="First">To tide the patient over a critical period of the disease in: <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2>6. Hematologic Disorders</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults; selected cases of secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>; Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2>7. Neoplastic Diseases</h2>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults and children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.8"></a><p></p>
<h2>8. Nervous System</h2>
<p class="First">Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.9"></a><p></p>
<h2>9. Ophthalmic Diseases</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> and ocular inflammatory conditions unresponsive to topical corticosteroids; <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>; sympathetic ophthalmia.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.10"></a><p></p>
<h2>10. Respiratory Diseases</h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>; idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>; fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy; <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (as distinct from <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">allergic asthma</span> listed above under "Allergic States"), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="45763750" conceptname="Idiopathic pulmonary fibrosis">idiopathic pulmonary fibrosis</span>, acute exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), and <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span> (PCP) associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic <span class="product-label-link" type="condition" conceptid="261053" conceptname="Pneumonia in aspergillosis">bronchopulmonary aspergillosis</span>, idiopathic <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span> with <span class="product-label-link" type="condition" conceptid="4045260" conceptname="Bronchiolitis obliterans organizing pneumonia">organizing pneumonia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.11"></a><p></p>
<h2>11. Rheumatic Disorders</h2>
<p class="First">As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low dose maintenance therapy); <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>; acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>; acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>; acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>; <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">epicondylitis</span>. For the treatment of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span> (<span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>), <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, Sjogren's syndrome, relapsing polychondritis, and certain cases of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.12"></a><p></p>
<h2>12. Miscellaneous</h2>
<p class="First">Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> with enlarged mediastinal lymph nodes causing respiratory difficulty, and <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> with pleural or <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> (appropriate antituberculous chemotherapy must be used concurrently when treating any <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the drug or any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (General)</h2>
<p class="First">Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen including viral, bacterial, fungal, protozoan or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infection</span>, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect humoral or cellular immunity, or neutrophil function. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe, and, with increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after it has already started.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (Viral)</h2>
<p class="First">Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affect the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi or viruses. The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2>Special pathogens</h2>
<p class="First">Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Mycobacterium, Ameba, Toxoplasma, Pneumocystis, Cryptococcus, Nocardia, etc.</p>
<p>Corticosteroids may activate latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>. Therefore, it is recommended that latent or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h2>
<p class="First">The use of prednisolone in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2>Vaccination</h2>
<p class="First"><span class="Bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, however, the response to such vaccines cannot be predicted.</span> Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>There is an enhanced effect of corticosteroids in patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., post-menopausal women) before initiating corticosteroid therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Neuro-psychiatric</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See <a href="#DA">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be warned not to discontinue the use of Millipred Oral Solution (10 mg Prednisolone per 5 mL) abruptly or without medical supervision, to advise any medical attendants that they are taking it, and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.9"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Millipred Oral Solution (10 mg Prednisolone per 5 mL) be increased.</p>
<p><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporin and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
<p>Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect.</p>
<p>Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.</p>
<p>Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
<p>Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
<p>When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., diuretics, amphotericin-B), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
<p>Due to inhibition of antibody response, patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. If possible, routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued.</p>
<p>Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
<p>Corticosteroids may suppress reactions to skin tests.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.10"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.10.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Prednisolone has been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which prednisolone has been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring. There are no adequate and well-controlled studies in pregnant women. Millipred Oral Solution (10 mg Prednisolone per 5 mL) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when Millipred Oral Solution (10 mg Prednisolone per 5 mL) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The efficacy and safety of prednisolone in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month of age). However, some of these conclusions and other indications for pediatric use of corticosteroid, e.g., severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.</p>
<p>The adverse effects of prednisolone in pediatric patients are similar to those in adults (see <a href="#AR">ADVERSE REACTIONS</a>). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of prednisolone sodium phosphate oral solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience with prednisolone sodium phosphate has not identified differences in responses between the elderly and younger patients. However, the incidence of corticosteroid-induced side effects may be increased in geriatric patients and appear to be dose-related. <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> is the most frequently encountered complication, which occurs at a higher incidence rate in corticosteroid-treated geriatric patients as compared to younger populations and in age-matched controls. Losses of bone mineral density appear to be greatest early on in the course of treatment and may recover over time after steroid withdrawal or use of lower doses (i.e., ≤5 mg/day). Prednisolone doses of 7.5 mg/day or higher have been associated with an increased relative risk of both vertebral and nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, even in the presence of higher bone density compared to patients with involutional <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.</p>
<p>Routine screening of geriatric patients, including regular assessments of bone mineral density and institution of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> prevention strategies along with regular review of prednisolone sodium phosphate indication should be undertaken to minimize complications and keep the dose at the lowest acceptable level. Co-administration of bisphosphonates has been shown to retard the rate of bone loss in corticosteroid-treated males and post-menopausal females, and these agents are recommended in the prevention and treatment of corticosteroid-induced <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.</p>
<p>It has been reported that equivalent weight-based doses yield higher total and unbound prednisolone plasma concentrations and reduced renal and non-renal clearance in elderly patients compared to younger populations. However, it is not clear whether dosing reductions would be necessary in elderly patients, since these pharmacokinetic alterations may be offset by age-related differences in responsiveness of target organs and/or less pronounced suppression of adrenal release of cortisol. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#CP">CLINICAL PHARMACOLOGY</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS (listed alphabetically under each subsection)</h1>
<p class="First"><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic cardiomyopathy</span> in premature infants.</p>
<p><span class="Bold">Dermatologic:</span> Facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing; may suppress reactions to skin tests; <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>; thin fragile skin; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Bold">Endocrine:</span> Decreased carbohydrate tolerance; development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; increased requirements for insulin or oral hypoglycemic agents in diabetic patients; manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus; menstrual irregularities; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness; suppression of growth in children.</p>
<p><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>:</span><br><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients; <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>; potassium loss; <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>; elevation in serum liver enzyme levels (usually reversible upon discontinuation); <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Bold">Metabolic:</span> Negative nitrogen balance due to protein catabolism.</p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads; loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>; <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>; pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones; <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>; <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>; vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
<p><span class="Bold">Neurological:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment; psychic disorders; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold">Ophthalmic:</span> <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>; <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>.</p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The effects of accidental ingestion of large quantities of prednisolone over a very short period of time have not been reported, but prolonged use of the drug can produce mental symptoms, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, abnormal fat deposits, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, excessive appetite, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, dry scaly skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, negative nitrogen balance with delayed bone and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span>, accentuated <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, decreased glucose tolerance, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> and abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> have been observed in children.</p>
<p>Treatment of acute overdosage is by immediate gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> followed by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of prednisolone may be reduced only temporarily, or alternate day treatment may be introduced.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The initial dosage of Millipred Oral Solution (10 mg Prednisolone per 5 mL) may vary from 2.5 mL to 30 mL (5 to 60 mg prednisolone base) per day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time, there is a lack of satisfactory clinical response, Millipred Oral Solution (10 mg Prednisolone per 5 mL) should be discontinued and the patient placed on other appropriate therapy. <span class="Bold">IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.</span> After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of Millipred Oral Solution (10 mg Prednisolone per 5 mL) for a period of time consistent with the patient's condition. If after long term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4 to 8 mg dexamethasone every other day for one month have been shown to be effective.</p>
<p>In pediatric patients, the initial dose of Millipred Oral Solution (10 mg Prednisolone per 5 mL) may vary depending on the specific disease entity being treated. The range of initial doses is 0.14 to 2 mg/kg/day in three or four divided doses (4 to 60 mg/m<span class="Sup">2</span>bsa/day).</p>
<p>The standard regimen used to treat <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in pediatric patients is 60 mg/m<span class="Sup">2</span>/day given in three divided doses for 4 weeks, followed by 4 weeks of single dose alternate-day therapy at 40 mg/m<span class="Sup">2</span>/day.</p>
<p>The National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic <span class="Italics">prednisone, prednisolone or methylprednisolone</span> in children whose <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> is uncontrolled by inhaled corticosteroids and long-acting bronchodilators is 1-2 mg/kg/day in single or divided doses. It is further recommended that short course, or "burst" therapy, be continued until a child achieves a peak expiratory flow rate of 80% of his or her personal best or symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse.</p>
<p><span class="Italics">For the purpose of comparison, 5 mL of Millipred Oral Solution (13.4 mg Prednisolone sodium phosphate) is equivalent to the following milligram dosage of the various glucocorticoids:</span></p>
<table width="70%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule" align="left">Cortisone, 50</td>
<td class="Rrule" align="left">Triamcinolone, 8</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Hydrocortisone, 40</td>
<td class="Rrule" align="left">Paramethasone, 4</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Prednisolone, 10</td>
<td class="Rrule" align="left">Betamethasone, 1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Prednisone, 10</td>
<td class="Rrule" align="left">Dexamethasone, 1.5</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Methylprednisolone, 8</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<p><span class="Italics">These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each 5 mL (teaspoonful) of Millipred Oral Solution contains 13.4 mg Prednisolone sodium phosphate (10 mg Prednisolone base) in a grape flavored solution.</p>
<p>NDC 16477-510-08 8 fl oz (237 mL) bottle</p>
<p>Dispense in tight, light-resistant glass or PET plastic containers as defined in the USP.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature].</span></p>
<p>Keep tightly closed and out of the reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured for:<br>Laser Pharmaceuticals, LLC<br>Greenville, SC 29615</p>
<p>Manufactured by:<br>Pharmaceutical Associates, Inc.<br>Greenville, SC 29605</p>
<p>Rev. 09/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 237 mL Bottle Label</h1>
<p class="First"><span class="Bold">NDC 16477-510-08</span></p>
<p><span class="Bold">Millipred™</span><br>(Prednisolone Sodium Phosphate<br>Oral Solution)<br><span class="Bold Italics">Equivalent to prednisolone</span></p>
<p><span class="Bold">10 mg/5 mL</span></p>
<p><span class="Bold">ALCOHOL FREE / DYE FREE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">8 fl oz (237 mL)</span></p>
<p><span class="Bold">LASER</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 237 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=12d46d10-00b9-45d5-81f9-e9b31083ae89&amp;name=millipred-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MILLIPRED 		
					</strong><br><span class="contentTableReg">prednisolone sodium phosphate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16477-510</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREDNISOLONE SODIUM PHOSPHATE</strong> (PREDNISOLONE) </td>
<td class="formItem">PREDNISOLONE SODIUM PHOSPHATE</td>
<td class="formItem">10 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span>) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16477-510-08</td>
<td class="formItem">237 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078465</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Laser Pharmaceuticals, LLC
							(614417132)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Pharmaceutical Associates, Inc. (044940096)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmaceutical Associates, Inc.</td>
<td class="formItem"></td>
<td class="formItem">044940096</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3b7e7191-d822-4b0d-8285-73e344c0f3ba</div>
<div>Set id: 12d46d10-00b9-45d5-81f9-e9b31083ae89</div>
<div>Version: 1</div>
<div>Effective Time: 20090901</div>
</div>
</div> <div class="DistributorName">Laser Pharmaceuticals, LLC</div></p>
</body></html>
